Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;9(5):e2401623.
doi: 10.1002/smtd.202401623. Epub 2025 Feb 9.

Versatile PLGA-Based Drug Delivery Systems for Tumor Immunotherapy

Affiliations
Review

Versatile PLGA-Based Drug Delivery Systems for Tumor Immunotherapy

Yishu Wang et al. Small Methods. 2025 May.

Abstract

Tumor immunotherapy, which utilizes the immune system to fight cancer, represents a revolutionary method for cancer treatment. Poly (lactic-co-glycolic acid) (PLGA) copolymer has emerged as a promising material for tumor immunotherapy due to its biocompatibility, biodegradability, and versatility in drug delivery. By tuning the size, shape, and surface properties of PLGA-based systems, researchers have improved their ability to align with the requirements for diverse tumor immunotherapy modalities. In this review, the basic properties of the PLGA materials are first introduced and further the principal forms of the PLGA systems for controlled release are summarized and delivery applications are targeted. In addition, recent advances in the use of PLGA delivery systems are highlighted to enhance antitumor immune responses in terms of tumor vaccines, immunogenic cell death-mediated immune responses, tumor microenvironment modulation, and combination immunotherapies. Finally, prospects for the future research and clinical translation of PLGA materials are proposed.

Keywords: PLGA; controlled release; immunogenic cell death; targeted delivery; tumor immunotherapy; tumor microenvironment; tumor vaccine.

PubMed Disclaimer

References

    1. a) B. Wang, S. Hu, Y. Teng, J. Chen, H. Wang, Y. Xu, K. Wang, J. Xu, Y. Cheng, X. Gao, Sig. Transduct. Target Ther. 2024, 9, 200;
    1. b) F. Yang, K. Shi, Y. P. Jia, Y. Hao, J. R. Peng, Z. Y. Qian, Acta. Pharmacol. Sin. 2020, 41, 911.
    1. B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen, L. Li, W. Wei, J. He, J. Natl. Cancer Cent. 2024, 4, 47.
    1. R. L. Siegel, A. N. Giaquinto, A. Jemal, CA Cancer J. Clin. 2024, 74, 12.
    1. T. Ye, F. Li, G. Ma, W. Wei, Adv. Drug Deliv. Rev. 2021, 177, 113927.

Publication types

Substances

LinkOut - more resources